MedTrace Logo

Study for the Early Diagnosis of Parkinson's Disease

NCT02283073 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 410

Last updated 2018-07-10

No results posted yet for this study

Summary

The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients. Differential diagnosis includes patients with Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia, Essential Tremor and Normal Controls.

Conditions

  • Parkinson's Disease, Idiopathic

Sponsors & Collaborators

  • Bio Shai Ltd.

    lead INDUSTRY

Principal Investigators

  • Ofer Gonen, MD · Assaf-Harofeh Medical Center

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Israel
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283073 on ClinicalTrials.gov